|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 320.53 USD | -1.28% |
|
+1.77% | +36.22% |
| Capitalization | 41.79B 35.86B 33.41B 31.09B 57.35B 3,599B 64.04B 404B 152B 1,688B 157B 154B 6,203B | P/E ratio 2025 * |
-422x | P/E ratio 2026 * | 158x |
|---|---|---|---|---|---|
| Enterprise value | 39.97B 34.3B 31.95B 29.73B 54.85B 3,442B 61.25B 386B 146B 1,614B 150B 147B 5,933B | EV / Sales 2025 * |
13.4x | EV / Sales 2026 * | 10.1x |
| Free-Float |
99.2% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Alnylam Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | -1.28% | ||
| 1 week | +1.77% | ||
| Current month | -1.71% | ||
| 1 month | +2.63% | ||
| 3 months | +36.65% | ||
| 6 months | +30.15% | ||
| Current year | +36.22% |
| 1 week | 309.57 |  | 329.87 |
| 1 month | 308.46 | | 333.7 |
| Current year | 205.87 | | 333.7 |
| 1 year | 205.87 | | 333.7 |
| 3 years | 135.46 | | 333.7 |
| 5 years | 117.58 | | 333.7 |
| 10 years | 31.38 | | 333.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 2021-12-31 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 57 | 2019-08-12 |
| Chief Tech/Sci/R&D Officer | - | 2023-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Dennis Ausiello
BRD | Director/Board Member | 79 | 2012-04-22 |
Amy Schulman
CHM | Chairman | 64 | 2023-01-04 |
Michael Bonney
CHM | Chairman | 66 | 2015-11-30 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 5.08% | 1 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.28% | +1.77% | +34.77% | +119.96% | 41.79B | ||
| +1.34% | -2.69% | -10.00% | +136.58% | 693B | ||
| +0.44% | +4.33% | +5.82% | -4.65% | 394B | ||
| -1.12% | -1.66% | +9.83% | +26.39% | 334B | ||
| -2.22% | -5.55% | -53.26% | -1.90% | 287B | ||
| +0.58% | +0.66% | -7.15% | -21.43% | 259B | ||
| -1.12% | -4.09% | -2.94% | +12.40% | 223B | ||
| -0.17% | -1.49% | -15.11% | -7.23% | 215B | ||
| -1.91% | -4.08% | -36.42% | -13.43% | 201B | ||
| -1.17% | -0.17% | -11.03% | +19.18% | 158B | ||
| Average | -0.66% | -1.40% | -8.55% | +26.59% | 280.67B | |
| Weighted average by Cap. | -0.24% | -1.61% | -10.69% | +36.37% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.97B 2.55B 2.38B 2.21B 4.08B 256B 4.55B 28.7B 10.84B 120B 11.15B 10.92B 441B | 3.91B 3.36B 3.13B 2.91B 5.37B 337B 5.99B 37.77B 14.26B 158B 14.67B 14.37B 580B |
| Net income | -101M -86.85M -80.92M -75.29M -139M -8.72B -155M -978M -369M -4.09B -380M -372M -15.02B | 258M 222M 206M 192M 354M 22.24B 396M 2.49B 941M 10.43B 969M 949M 38.33B |
| Net Debt | -1.82B -1.56B -1.46B -1.36B -2.5B -157B -2.79B -17.6B -6.64B -73.59B -6.84B -6.69B -271B | -2.4B -2.06B -1.92B -1.78B -3.29B -207B -3.68B -23.18B -8.75B -96.9B -9B -8.81B -356B |
More financial data
* Estimated data
Employees
2,230
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-07-18 | 320.53 $ | -1.28% | 581,322 |
| 25-07-17 | 324.69 $ | +0.58% | 744,566 |
| 25-07-16 | 322.81 $ | +3.76% | 1,234,188 |
| 25-07-15 | 311.12 $ | -1.47% | 927,335 |
| 25-07-14 | 315.75 $ | +0.26% | 629,609 |
Delayed Quote Nasdaq, July 18, 2025 at 04:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
320.53USD
Average target price
332.06USD
Spread / Average Target
+3.60%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ALNY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition